HDACi with multiple targets have also been developed and tested in clinical trials, such as the dual HDAC and phosphoinositide-3 kinase (PI3K) inhibitor CUDC-907 (also called fimepinostat), which has been reported to inhibit Myc transcriptional expression and reduce Myc-mediated proliferation of multiple cancer cell lines (Pei et al., 2016; Kotian et al., 2017; Pal et al., 2018; Guo et al., 2019). Here, HDAC9 is linked to cancer.